1. Home
  2. HALO
  3. HALO News

Latest Halozyme Therapeutics Inc. (HALO) News on August 1, 2025

HALO

Argus Research

a month ago

HALO: Raising target price to $59.00

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
HALO

PR Newswire

a month ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

a month ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
HALO

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO

Zacks

2 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
HALO

Zacks

2 months ago

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?

HALO

Argus Research

2 months ago

HALO: What does Argus have to say about HALO?

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
HALO

Zacks

2 months ago

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
HALO

TipRanks

2 months ago

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo

Merck granted review of Halozyme patent claims by PTAB
HALO

TipRanks

2 months ago

Merck granted review of Halozyme patent claims by PTAB

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme
HALO

Zacks

2 months ago

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme

This week in Trumponomics: Too bad TACO isn’t true
HALO

Yahoo Finance

2 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right
HALO

The Guardian

2 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
HALO

Yahoo Finance Video

2 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says
HALO

Reuters

2 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
HALO

USA TODAY

2 months ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
HALO

Simply Wall St.

2 months ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"
HALO

CBS News Videos

2 months ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate
HALO

Simply Wall St.

2 months ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
HALO

Zacks

2 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Halozyme to Participate at Upcoming Investor Conferences
HALO

PR Newswire

2 months ago

Halozyme to Participate at Upcoming Investor Conferences

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
HALO

Zacks

2 months ago

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)

HALO

MT Newswires

2 months ago

Update: Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo

Implied Volatility Surging for Halozyme Therapeutics Stock Options
HALO

Zacks

2 months ago

Implied Volatility Surging for Halozyme Therapeutics Stock Options

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
HALO

Zacks

2 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
HALO

PR Newswire

2 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

High Growth Tech Stocks To Watch In The US May 2025
HALO

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch In The US May 2025

HALO

Argus Research

2 months ago

HALO: Raising target price to $59.00

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme
HALO

Zacks

3 months ago

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Shares Fall After Morgan Stanley Downgrade

4 Stocks With Impressive Interest Coverage Ratio to Buy Now
HALO

Zacks

3 months ago

4 Stocks With Impressive Interest Coverage Ratio to Buy Now

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance
HALO

TipRanks

3 months ago

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday
HALO

Insider Monkey

3 months ago

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday

HALO

MT Newswires

3 months ago

Morgan Stanley Downgrades Halozyme Therapeutics to Equalweight From Overweight, Adjusts Price Target to $62 From $73

HALO

Argus Research

3 months ago

HALO: Lowering target price to $55.00

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
HALO

Investor's Business Daily

3 months ago

Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News

HALO

MT Newswires

3 months ago

Halozyme Shares Fall After Leerink Partners Downgrade

Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?

HALO

MT Newswires

3 months ago

Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47

Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?
HALO

Insider Monkey

3 months ago

Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now?

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
HALO

Zacks

3 months ago

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
HALO

Zacks

3 months ago

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points
HALO

Investor's Business Daily

3 months ago

S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy?

Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain
HALO

Insider Monkey

3 months ago

Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain

HALO

MT Newswires

3 months ago

William O'Neil Initiates Halozyme Therapeutics at Buy

Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations
HALO

Simply Wall St.

3 months ago

Halozyme Therapeutics First Quarter 2025 Earnings: Beats Expectations

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday
HALO

Insider Monkey

3 months ago

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday

HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
HALO

Zacks

3 months ago

HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View

HALO

MT Newswires

3 months ago

Morgan Stanley Raises Price Target on Halozyme Therapeutics to $73 From $67, Keeps Overweight Rating

Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
HALO

GuruFocus.com

3 months ago

Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

HALO

Argus Research

3 months ago

HALO: Lowering target price to $65.00

Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Q1 Adjusted EPS, Revenue Increase, Boosts 2025 Outlook; Shares Rise

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
HALO

PR Newswire

3 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
HALO

PR Newswire

3 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
HALO

Zacks

3 months ago

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

High Growth Tech Stocks in the US Market
HALO

Simply Wall St.

3 months ago

High Growth Tech Stocks in the US Market

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
HALO

Zacks

3 months ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation

Halozyme to Report First Quarter 2025 Financial and Operating Results
HALO

PR Newswire

3 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
HALO

PR Newswire

3 months ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme sues Merck; FDA blames cuts for Vanda delay
HALO

BioPharma Dive

3 months ago

Halozyme sues Merck; FDA blames cuts for Vanda delay

HALO

MT Newswires

3 months ago

Sector Update: Health Care

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

HALO

MT Newswires

3 months ago

Halozyme Therapeutics Sues Merck for Alleged Patent Infringement

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
HALO

PR Newswire

3 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
HALO

Simply Wall St.

4 months ago

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

HALO

Argus Research

4 months ago

HALO: Raising target price to $67.00

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
HALO

Investor's Business Daily

4 months ago

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

HALO

MT Newswires

4 months ago

Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
HALO

PR Newswire

4 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

HALO

MT Newswires

4 months ago

Halozyme Says European Commission Approves Darzalex Co-Formulated With Enhanze to Treat Multiple Myeloma

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
HALO

PR Newswire

4 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

HALO

Argus Research

4 months ago

HALO: Rating increased to a BUY

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
HALO

Zacks

4 months ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

HALO

MT Newswires

4 months ago

Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
HALO

PR Newswire

4 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

HALO

Argus Research

4 months ago

HALO: Lowering target price to $65.00

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
HALO

PR Newswire

4 months ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
HALO

Zacks

4 months ago

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
HALO

Zacks

4 months ago

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

HALO

Argus Research

4 months ago

HALO: Raising target price to $68.00

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
HALO

Zacks

4 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
HALO

Zacks

4 months ago

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Halozyme Joins the $1 Billion Club
HALO

FX Empire

4 months ago

Halozyme Joins the $1 Billion Club

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
HALO

Investor's Business Daily

5 months ago

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
HALO

Zacks

5 months ago

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

HALO vs. AMGN: Which Stock Is the Better Value Option?
HALO

Zacks

5 months ago

HALO vs. AMGN: Which Stock Is the Better Value Option?

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
HALO

Insider Monkey

5 months ago

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.
HALO

Barrons.com

5 months ago

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

High Growth Tech Stocks To Watch In US March 2025
HALO

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In US March 2025

HALO

MT Newswires

5 months ago

Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
HALO

The Wall Street Journal

5 months ago

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
HALO

Zacks

5 months ago

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

HALO

MT Newswires

5 months ago

Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

HALO

Argus Research

5 months ago

HALO: What does Argus have to say about HALO?

HALO

MT Newswires

5 months ago

Halozyme Therapeutics Insider Sold Shares Worth $1,260,681, According to a Recent SEC Filing

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
HALO

PR Newswire

5 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Share on Social Networks: